- Home
- TRMB vs GMAB Comparison
TRMB vs GMAB Comparison
Compare TRMB & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMB
- GMAB
- Stock Information
- Founded
- TRMB 1978
- GMAB 1999
- Country
- TRMB United States
- GMAB Denmark
- Employees
- TRMB N/A
- GMAB N/A
- Industry
- TRMB Industrial Machinery/Components
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- TRMB Industrials
- GMAB Health Care
- Exchange
- TRMB Nasdaq
- GMAB Nasdaq
- Market Cap
- TRMB 19.2B
- GMAB 17.4B
- IPO Year
- TRMB 1990
- GMAB N/A
- Fundamental
- Price
- TRMB $78.87
- GMAB $28.67
- Analyst Decision
- TRMB Buy
- GMAB Strong Buy
- Analyst Count
- TRMB 7
- GMAB 7
- Target Price
- TRMB $92.00
- GMAB $41.17
- AVG Volume (30 Days)
- TRMB 1.1M
- GMAB 2.7M
- Earning Date
- TRMB 11-05-2025
- GMAB 11-06-2025
- Dividend Yield
- TRMB N/A
- GMAB N/A
- EPS Growth
- TRMB N/A
- GMAB 77.72
- EPS
- TRMB 1.18
- GMAB 21.62
- Revenue
- TRMB $3,575,500,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- TRMB N/A
- GMAB $24.25
- Revenue Next Year
- TRMB $6.82
- GMAB $16.29
- P/E Ratio
- TRMB $67.56
- GMAB $13.03
- Revenue Growth
- TRMB N/A
- GMAB 32.97
- 52 Week Low
- TRMB $52.91
- GMAB $17.24
- 52 Week High
- TRMB $87.50
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- TRMB 46.47
- GMAB 36.68
- Support Level
- TRMB $78.50
- GMAB $29.57
- Resistance Level
- TRMB $82.47
- GMAB $29.30
- Average True Range (ATR)
- TRMB 1.76
- GMAB 0.69
- MACD
- TRMB 0.15
- GMAB -0.61
- Stochastic Oscillator
- TRMB 49.54
- GMAB 0.19
About TRMB Trimble Inc.
Trimble Inc is a technology solutions provider that enables office and mobile professionals to connect their workflows and asset lifecycles to drive a more productive, sustainable future. The company has three reportable segments: Architects, Engineers, Construction, and Owners (AECO). This segment provides software solutions that sell through a direct channel to customers in the construction industry. Field Systems. This segment provides hardware and associated software solutions that sell through dealer partner channels. Transportation and Logistics (T&L). This segment provides solutions for customers working in long-haul trucking and freight shipping markets.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.